About: http://data.cimple.eu/news-article/0a063ea0e171960359ad5cf0971655f27b80b12d26592aef6cdb1062     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

AttributesValues
rdf:type
schema:articleBody
  • Clinical trials in Brazil of a Chinese-made vaccine against Covid-19 have shown "extremely positive" results, and a widespread vaccination campaign could begin as early as December, the governor of Sao Paulo state said Wednesday. Sao Paulo, the epicenter of the coronavirus pandemic in hard-hit Brazil, is one of six states helping to test the so-called CoronaVac vaccine developed by Chinese pharmaceutical firm Sinovac Biotech. The vaccine produced an immune response in 98 percent of recipients over 60 years old, with no adverse side-effects reported so far, said Governor Joao Doria. "The results have been extremely positive," he told a news conference. "We will soon be able to immunize Brazilians in Sao Paulo and across the country with the CoronaVac vaccine.... The projected delivery date is in December this year." Sinovac has partnered with a Brazilian public health research center, the Butantan Institute, to conduct Phase 3 clinical trials of the vaccine -- the last step before regulatory approval. The deal gives the institute the right to produce 120 million doses of the vaccine, according to officials. CoronaVac has gotten caught up in a political battle in Brazil, however. President Jair Bolsonaro, whose administration has tense relations with China, has criticized the vaccine, and lashed out at Doria, a leading opponent, for supposedly backing it. The far-right president has instead allocated 1.9 billion reals ($360 million) to purchase another vaccine candidate, developed by Oxford University and pharmaceutical firm AstraZeneca. Trials of that vaccine, which is also being tested partly in Brazil, were suspended Tuesday after a volunteer recipient developed an unexplained illness -- a move the company described as "routine." Brazil has the second-highest death toll in the pandemic after the United States, with more than 127,000 people killed and 4.1 million infections. The South American country has emerged as a leading testing ground for vaccines. In the latest development, Brazilian medical diagnostics company Dasa and US vaccine-maker COVAXX announced a deal Wednesday to conduct Phase 2 and 3 trials of the latter's Covid-19 vaccine in Brazil. COVAXX, a subsidiary of US firm United Biomedical, plans to test the vaccine on at least 3,000 volunteers in Brazil. jhb/st
schema:headline
  • Brazil could launch Chinese Covid-19 vaccine this year: governor
schema:mentions
schema:author
schema:datePublished
http://data.cimple...sPoliticalLeaning
http://data.cimple...logy#hasSentiment
http://data.cimple...readability_score
http://data.cimple...tology#hasEmotion
Faceted Search & Find service v1.16.115 as of Oct 09 2023


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 3 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software